Valeant Lays Off 77 Dendreon Workers in Seattle

Layoffs began after completion of the $495 million sale of Dendreon’s prostate cancer drug and other assets
March 3, 2015

Valeant Pharmaceuticals International is laying off 77 employees at Seattle-based Dendreon’s operations, according to a WARN notice received by the state Employment Security Department.

An article in The Seattle Times said the layoffs began Feb. 23, immediately after completion of the $495 million sale of Dendreon’s prostate cancer drug, Provenge, and other assets.

The article went on to say that Valeant spokeswoman Laurie Little said, “most of these positions were in G&A functions where there was overlap with Valeant’s existing businesses, especially in corporate and back office functions.”

Read the full story

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates